Home / Business and Economy / Pharma Giants Sue Amgen Over Cancer Drug Biosimilar

Pharma Giants Sue Amgen Over Cancer Drug Biosimilar

16 Sep

Summary

Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen.
The lawsuit aims to block Amgen's proposed Opdivo biosimilar.
The case was filed in Delaware federal court on September 15, 2026.

Bristol Myers Squibb and Ono Pharmaceutical initiated legal proceedings on September 15, 2026, filing a lawsuit in Delaware federal court against Amgen. The core of the litigation is Amgen's proposed U.S. biosimilar of Opdivo, a highly successful cancer immunotherapy drug developed by BMS and Ono.

This lawsuit aims to block the market entry of Amgen's biosimilar. The case, identified as Bristol-Myers Squibb Co. v. Amgen Inc., has been lodged with the U.S. District Court for the District of Delaware. Legal teams for both parties have been assigned, with the case being reported from Washington.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.